Nashville Top 30 Under 30 - Class of 2023
Top 30 Under 30 is a 16–week recognition program and philanthropic competition honoring Music City’s brightest young professionals. Honorees are display their community involvement and highlight their professional achievements, while competitively raising funds to provide all people with cystic fibrosis the opportunity to lead full, productive lives.
In just sixteen weeks, the Class of 2023, raised $302,316 for the Cystic Fibrosis Foundation - Tennessee Chapter.
Many thanks to the 95 individuals and companies who donated to my campaign, or donated goods & services for fundraising events. Thanks to your generosity we raised $27,610. The third highest amount in the Class.
My Journey
![[Original size] CF Thank You (4 × 6 in).png](https://static.wixstatic.com/media/f6ec85_d4fab67780dd4188ac30d09dd921006d~mv2.png/v1/fill/w_95,h_143,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/%5BOriginal%20size%5D%20CF%20Thank%20You%20(4%20%C3%97%206%20in).png)
Many thanks to the 95 individuals and companies who donated to my campaign, or donated goods & services for fundraising events.
Thanks to your generosity we raised $27,610.
The third highest amount in the Class.
What is Cystic Fibrosis?
CF is a progressive, genetic disease that affects the lungs, pancreas, and other organs. There are close to 40,000 children and adults living with CF in the United States and thanks to continued medical advancements it was recently announced that the average life expectancy of someone with CF is 56 (previously 40).
The Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for CF and supports a broad range of research initiatives to tackle the disease from all angles.
They facilitate the development of promising drugs and therapies. Clinical trials that test these are a major part of CF research, and they take place at Foundation-accredited care centers all over the US; and their drug development pipeline enables you to track the progress of these potential therapies, whether or not you're part of the clinical trial.